FRANKLIN LAKES, N.J., Feb. 12, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD CLiC™ System during the 2016 Advances in Genome Biology and Technology (AGBT) Meeting.
The BD CLiC System enables genomic research by providing cost effective NGS library preparation with limited operator intervention. The BD CLiC System is a high-throughput, fully integrated, next generation sequencing (NGS) library prep instrument, engineered for targeted and whole genome library preparation. The system features the flexibility to scale between 24 and 96 samples per run allowing the ability to process more than 50,000 samples per year.
The BD CLiC is the first high-throughput, NGS system to consolidate the entire NGS library preparation workflow process into a single instrument, which has been demonstrated to significantly reduce the labor time of laboratory technicians as compared to traditional methods. The "walkaway" automation capability, from purified DNA sample to sequence-ready barcoded libraries, can help reduce the risk of human error.
"The addition of the BD CLiC System expands the company's presence in genomics and further demonstrates BD's commitment to developing platforms and reagents that simplify complex workflows and enable new applications for life science researchers," said Stephen Gunstream, vice president of global genomics at BD.
The BD CLiC System utilizes the proprietary Composite Liquid Cell (CLC) technology. This technology encapsulates reactions in microdroplets, significantly reducing the use of plastic consumables and expensive reagents. The CLiC is ideal for the automation of complex genomic protocols that require sequential reagent addition and purification steps.
The BD CLiC System, BD FACSseq™ Cell Sorter and BD™ Precise Assays will be on display at the 2016 AGBT congress in the Marbella I suite. The BD CLiC System is already being used by early access customers and is now commercially available for research use.
For more information, please visit: www.bd.com/agbt.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.
Contacts: Matt Coppola BD Public Relations 201.847.7370 email@example.com
Monique N. Dolecki BD Investor Relations 201.847.5378 Monique_Dolecki@bd.com
SOURCE BD (Becton, Dickinson and Company)